Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7386 in Combination With Pembrolizumab ± Lenvatinib in Previously Treated Solid Tumors
2023-505425-14-00Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of e7386 in melanoma, colorectal cancer (CRC) and hepatocellular carcinoma (HCC) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Dose-limiting toxicities (DLTs) in phase 1b and Overall response rate (ORR) in phase 2. Started Feb 2024; status: completed.
02
Drugs
e7386
03
Conditions
melanomacolorectal cancer (CRC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-505425-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505425-14-00.